Search results for Anti-PD-L1 Antibody

Anti-PD-L1 Antibody, Covalab, Ref 00123747

Anti-PD-L1 antibody [ABM4E54], Abcam, AB210931

Anti-PD-L1 antibody [BLR020E], Abcam, AB243877

REACH authorisation Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances. It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses. This product is sold under License from Bethyl Laboratories, Inc.

Anti-PD-L1 antibody [CAL10], Abcam, AB237726

What is this antibody validated in? Anti-PD-L1 antibody [CAL10] (ab237726) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC-P), Immunocytochemistry/immunofluorescence (ICC/IF), ELISA, Multiplex IHC (mIHC) in Human, samples. What is the molecular weight of PD-L1? Anti-PD-L1 [CAL10] (ab237726) specifically detects a band for PD-L1 (UniProt: Q9NZQ7) at a molecular weight of 33kDa. Trusted by the scientific community Anti-PD-L1 [CAL10] (ab237726) was first used in a scientific publication in 2018 and has been cited over 10 times in peer-reviewed journals. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10μl. Discover our selection of trial-size antibodies. Specificity confirmed The specificity of Anti-PD-L1 antibody [CAL10] (ab237726) has been confirmed by Western blot testing in CD274 Knockout A549 cell line, ab267054 . Other related products We have a range of other formats of antibody clone [CAL10] also available for your convenience: ab237726, Carrier free - ab251611 , Alexa Fluor® 647 - ab267565 , ab279292 , ab279293 , ab279294 , Carrier free - ab279304 , Carrier free - ab279305 , Carrier free - ab279306 , Alexa Fluor® 555 - ab307643

Anti-PD-L1 antibody [EPR19759], Abcam, AB213524

Anti-PD-L1 antibody [EPR19759] (ab213524) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-P, IP, WB in human samples. Anti-PD-L1 antibody [EPR19759] (ab213524) has been cited over 96 times in peer reviewed journals and is trusted by the scientific community. Abcams high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [EPR19759] (ab213524) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-PD-L1 antibody [EPR19759] (ab213524) has been confirmed by testing in knockout samples. Anti-PD-L1 antibody [EPR19759] (ab213524) specifically detects PD-L1 (UniProt ID: Q9NZQ7; Molecular weight: 31kDa) and is sold in 100 uL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EPR19759 - ab221612 . Antibody clone EPR19759 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 488, Alexa Fluor® 647, HRP, Alexa Fluor® 594, Alexa Fluor® 568 ( ab214958 , ab215251 , ab215349 , ab216742 , ab22314 ). Programmed death-ligand 1 (PD-L1) is a critical protein in immuno-oncology, playing a significant role in tumor immune evasion. It is expressed on the surface of tumor cells and binds to the PD-1 receptor on T cells, inhibiting their activity and allowing tumors to escape immune detection. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-PD-L1 antibody [EPR20529], Abcam, AB213480

Anti-PD-L1 antibody [EPR20529] (ab213480) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ICC/IF, IP and WB. Abcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [EPR20529] (ab213480) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-PD-L1 antibody [EPR20529] (ab213480) has been confirmed by Western Blot testing in PD-L1 knockout MEF (mouse embryonic fibroblast) cells. Anti-PD-L1 antibody [EPR20529] (ab213480) has 5 independent reviews from customers. Anti-PD-L1 antibody [EPR20529] (ab213480) specifically detects PD-L1 (UniProt ID: Q9EP73; Molecular weight: 31kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EPR20529 - ab223141 . Programmed death-ligand 1 (PD-L1) is a critical protein in immuno-oncology, playing a significant role in tumor immune evasion. It is expressed on the surface of tumor cells and binds to the PD-1 receptor on T cells, inhibiting their activity and allowing tumors to escape immune detection. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-PD-L1 antibody [MIH5], Abcam, AB269253

Anti-PD-L1 antibody [RM1012], Abcam, AB282458

What are recombinant multiclonals? Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including: - The sensitivity of polyclonal antibodies by recognising multiple epitopes - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production View our range of recombinant multiclonal antibodies . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .

Anti-PD-L1 antibody [28-8], Abcam, AB205921

Anti-PD-L1 antibody [28-8] (ab205921) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt, ICC/IF, IHC-Fr, IHC-P, WB, mIHC in human samples. Anti-PD-L1 antibody [28-8] (ab205921) has been cited over 476 times in peer reviewed journals and is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [28-8] (ab205921) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-PD-L1 antibody [28-8] (ab205921) has been confirmed by testing in knockout samples. Anti-PD-L1 antibody [28-8] (ab205921) has 13 independent reviews from customers. Anti-PD-L1 antibody [28-8] (ab205921) specifically detects PD-L1 (UniProt ID: Q9NZQ7; Molecular weight: 31kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (50 µL). Conjugation-ready, carrier free format available for antibody clone 28-8 - ab228413 . Antibody clone 28-8 is also available pre-conjugated to a variety of labels for your convenience - HRP, PE, Alexa Fluor® 555, Alexa Fluor® 568, Alexa Fluor® 594, FITC ( ab209961 , ab209962 , ab213358 , ab213359 , ab213360 , ab224027 ). PD-L1 (Programmed Death-Ligand 1) is a protein that plays a significant role in oncology, particularly in the immune response to cancer. It is expressed on the surface of cancer cells and interacts with the PD-1 receptor on T-cells, effectively inhibiting the immune system's ability to attack the tumor. This interaction is a key target for immunotherapy drugs, such as checkpoint inhibitors, which block the PD-1/PD-L1 pathway, allowing the immune system to recognize and destroy cancer cells. FURTHER INFORMATION ON POSITIVE CONTROLS ( Chinese version ) Tissue: - Tonsil - with hyperreactive changes. Screening of hyper-reactive tonsils is recommended to find tonsil with the highest expression of PD-L1 in crypt epithelium, macrophages homing the germinal centers and interfollicular mononuclear leukocytes. - Tumor tissues - prescreened for positive tumor and inflammatory infiltrates. PD-L1 expression varies by tumor type so screening is recommended to find positive and negative tumor controls. - The following publication is useful for finding suitable tumor types for PD-L1 expression: http://www.immunotherapyofcancer.org/content/1/S1/P53 - Note: Look for specimens with high numbers of inflammatory macrophages and mononuclear leukocytes. Cell Lines: - Positive controls: B-CPAP (high), ES-2 (medium), HCC70 (low). Primary antibody negative control: Recombinant Rabbit IgG isotype control antibody, ab172730 . Recombinant protein positive control: Recombinant human PD-L1 protein, ab167713 . Immunohistochemistry usage: For IHC usage on FFPE tissues, we recommend using PD-L1 IHC panel ab236676 , which contains PD-L1 antibody clone 28-8 (ab205921), HIER antigen retrieval reagent ( ab208572 ) and IHC detection kit HRP/DAB ( ab209101 ). Western blot usage: For clone 28-8, it is recommended to use Odyssey system. This system has the advantages of a wider dynamic range and less background than chemiluminescence. This PD-L1 antibody [28-8] has been used as detector antibody in Human PD-L1 SimpleStep ELISA ® kit: ab214565 and ab277712 . To support you in your biomarker discovery and validation studies, we offer a comprehensive suite of solutions including high quality, validated recombinant antibodies and assay kits. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-PD-L1 antibody [29E.2A3], Abcam, AB259283